Tag

Daraxonrasib

All articles tagged with #daraxonrasib

health2 days ago•23 min saved

Charleston Gains Access to Breakthrough KRAS Pancreatic Cancer Drug

Charleston-area patients with metastatic pancreatic cancer are receiving daraxonrasib, a KRAS-targeted drug that showed in Phase 3 trials to roughly double median survival (about 13.2 months versus 6.6 with chemotherapy) via an expanded-access program before FDA approval. Terri Truere became the first local patient treated at Roper St. Francis Cancer Center, a development clinicians say could improve targeting of the KRAS mutation and potentially expand surgical options, though the drug carries notable side effects such as mouth sores, sore throat and rash. The rollout offers optimism for pancreatic cancer treatment and for next-generation KRAS therapies.

via Post and Courier|

#charleston #daraxonrasib #expanded-access

health2 days ago•59 min saved

KRAS-targeting pancreatic cancer drug boosts survival, reaches Charleston patients

A Phase 3 trial showed daraxonrasib, a KRAS-targeting therapy for metastatic pancreatic cancer, nearly doubles median survival (about 13.2 months vs 6.6) and is moving into expanded-access programs, with Terri Truere in Charleston among the first patients in the area to receive it ahead of FDA approval. The drug is not yet approved, but more SC sites are preparing to offer it; it carries notable side effects such as mouth sores and rash, and access remains limited. Doctors see promise that KRAS targeting could improve outcomes and potentially expand surgical eligibility in some patients.

via Yahoo|

#charleston #daraxonrasib #expanded-access

health9 days ago•0 min saved

Investigational pancreatic cancer pill may double survival, early data suggest

An investigational drug called daraxonrasib given to a pancreatic cancer patient at Massachusetts General Hospital is described as a potential breakthrough, with early results indicating that survival could be doubled. The report frames this as a historic advance after decades of research, though access to full details currently requires login or subscription to the Globe.

via The Boston Globe|

#cancer-treatment #clinical-trial #daraxonrasib

health13 days ago•3 min saved

KRAS-targeting drug offers renewed hope in advanced pancreatic cancer

An experimental KRAS-inhibiting pill, daraxonrasib, significantly extends median survival in advanced pancreatic cancer (13.2 months vs. 6.7 months with chemotherapy) in a phase 3 trial, and is available to eligible patients via the FDA Expanded Access Protocol at 10 Intermountain Health hospitals while full approval is pending; it’s a second-line option with manageable side effects and is not a cure.

via USA Today|

#daraxonrasib #expanded-access-protocol #health

health14 days ago•17 min saved

Promising KRAS-targeting drug daraxonrasib doubles survival in late-stage pancreatic cancer

Daraxonrasib, a KRAS-targeting drug for stage 4 pancreatic cancer, doubled survival in trials (6.7 to 13.2 months) and is being provided through an Extended Access Program ahead of FDA approval; nine Intermountain Health patients are enrolled. It is not a cure and carries side effects like rash, diarrhea, and mouth sores.

via ksl.com|

#daraxonrasib #extended-access-program #fda-approval

health15 days ago•3 min saved

Daraxonrasib Goes to Patients Early Through Expanded Access Ahead of FDA Decision

Following dramatic RASolute 302 results, physicians nationwide are offering the oral RAS inhibitor daraxonrasib to patients under expanded-access programs before FDA approval. The drug nearly doubled median overall survival in previously treated metastatic pancreatic cancer (6.7 to 13.2 months) and Revolution Medicines has filed for FDA approval. More than 2,000 patients are on EAP, with sites across the U.S.; institutions cover IRB and safety monitoring costs. Huntsman Cancer Institute reported about 50 patients through its EAP; setup takes 2–3 weeks and delivery occurs in about 7–10 days after consent. Side effects include skin toxicity, managed with dermatology input and topical/doxycycline. Trials continue in first-line metastatic pancreatic cancer, post-surgery settings, and second-line RAS-mutant NSCLC.

via Medscape|

#daraxonrasib #expanded-access-program #fda-approval

health17 days ago•7 min saved

Illinois patients begin expanded-access rollout of experimental pancreatic cancer drug

Illinois and other states are starting to treat metastatic pancreatic cancer patients with the experimental drug daraxonrasib under an FDA-expanded access program ahead of full FDA approval; early clinical data show a median survival of about 13 months with daraxonrasib versus about six months with additional chemotherapy, with doctors calling it a potential game changer. The drug is provided at no cost through Revolution Medicines, and physicians submit requests for each patient as several Illinois hospitals begin offering it.

via chicagotribune.com|

#city-of-hope-chicago #clinical-trial #daraxonrasib

biotech1 month ago•2 min saved

Pancreatic cancer braces for post-daraxonrasib era

At a European pancreatic cancer conference, experts hailed the anticipated launch of daraxonrasib as a potential milestone that could reshape care, echoing the impact of checkpoint inhibitors. But they warned the new therapy would bring opportunities and challenges—from access and pricing to real-world effectiveness and how it will be integrated into standard treatment and combination strategies as data emerge.

via STAT|

#biotech #clinical-trials #daraxonrasib

health1 month ago•21 min saved

Pancreatic cancer breakthrough prompts shift toward early-detection era

A new pancreatic cancer drug, daraxonrasib, has shown the ability to double median survival in advanced cases versus chemotherapy, fueling optimism about treating the disease earlier. At UC San Diego’s Moores Cancer Center, researchers note that early intervention could maximize benefits as part of PRECEDE, a global program screening at‑risk individuals with regular blood tests and imaging across 65 centers, with about 12,000 of 20,000 enrolled and roughly 75% of detected cases currently found at stage I. AI in imaging is anticipated to boost early detection, while the FDA has granted expanded access to the drug for patients not eligible for trials. Experts envision “interception studies” that could use RAS inhibitors earlier to prevent spread, potentially combining resection with targeted therapy for even better outcomes.

via San Diego Union-Tribune|

#daraxonrasib #early-detection #health

biotech1 month ago•3 min saved

KRAS combo data prompts Revolution Medicines toward Phase 3

Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.

via Endpoints News|

#biotech #daraxonrasib #esmo

health2 months ago•3 min saved

RAS-targeting drug daraxonrasib nearly doubles median survival in pancreatic cancer trial

A phase 3 trial published in the New England Journal of Medicine finds the oral RAS-inhibitor daraxonrasib significantly improves survival for metastatic pancreatic cancer, with a median of 13.2 months versus 6.7 months with chemotherapy; the FDA has granted an early-access program ahead of potential approval later in 2026, marking a potential paradigm shift by directly targeting mutant RAS to halt cancer growth.

via USA Today|

#daraxonrasib #health #pancreatic-cancer

healthcare2 months ago•2 min saved

Access race tightens as Revolution Medicines' pancreatic cancer drug nears approval

Patients with pancreatic cancer are pursuing Revolution Medicines' experimental drug daraxonrasib through expanded-access programs as the company nears potential approval. While there is optimism the treatment could extend lives, demand is surging and production may not keep up, raising concerns about who receives the drug first and how access will be allocated.

via statnews.com|

#daraxonrasib #drug-access #expanded-access

healthcare2 months ago•2 min saved

Daraxonrasib Poised to Redefine Second-Line Pancreatic Cancer Care

Revolution Medicines’ daraxonrasib is expected to gain FDA approval for metastatic pancreatic cancer soon and could rapidly become the standard second-line therapy, with discussions about expanding use to newly diagnosed metastatic cases; the main gating factor is the speed of FDA submission.

via statnews.com|

#asco #daraxonrasib #fda-approval

health2 months ago•10 min saved

KRAS-Targeting Drug daraxonrasib Delivers Major Survival Gain in Pancreatic Cancer

A phase trial found daraxonrasib, a pan-RAS inhibitor that targets KRAS, nearly doubles survival for patients with advanced pancreatic cancer (median ~15 months vs historically under 8). The FDA granted Breakthrough Therapy and Orphan Drug designations and expanded-access use ahead of potential full approval later in 2026. While not a cure, the drug offers meaningful survival benefit with manageable side effects, and researchers are exploring combination therapies and immunotherapy approaches.

via UCHealth|

#clinical-trial #daraxonrasib #fda-breakthrough-therapy

health2 months ago•10 min saved

First-in-class KRAS therapy boosts survival in metastatic pancreatic cancer

A new oral drug, daraxonrasib, targets the KRAS-driven mechanism in pancreatic cancer by engaging cyclophilin A to shut down KRAS signaling. In a Phase 3 trial of 500 patients with metastatic pancreatic cancer who had prior treatment, daraxonrasib nearly doubled median survival from 6.7 to 13.2 months and reduced the risk of death by about 60% versus standard chemotherapy. The most common side effects were a skin rash, stomatitis, diarrhea, nausea and vomiting, though discontinuation due to adverse effects was lower and quality of life improved. Regulatory review by the FDA and other global authorities is the immediate next step, with expedited review likely; if approved, the drug could reach clinics within months and herald a shift toward targeted, personalized therapy and potential combination approaches to prevent resistance.

via The Conversation|

#daraxonrasib #health #kras